{"id":"NCT00841763","sponsor":"Novartis","briefTitle":"Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","officialTitle":"A Phase III, Randomized, Controlled, Observer-blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted With MF59 (Fluad-H5N1) in Adult and Elderly Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-04","completion":"2009-11","firstPosted":"2009-02-11","resultsPosted":"2013-01-18","lastUpdate":"2021-04-23"},"enrollment":3647,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Pandemic Influenza Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Placebo (PL)","otherNames":[]},{"type":"BIOLOGICAL","name":"Trivalent influenza virus vaccine (TIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Adjuvanted monovalent influenza virus vaccine (aH5N1)","otherNames":[]},{"type":"BIOLOGICAL","name":"Adjuvanted trivalent influenza virus vaccine (aTIV)","otherNames":[]}],"arms":[{"label":"TIV + aH5N1","type":"EXPERIMENTAL"},{"label":"PL + aTIV","type":"ACTIVE_COMPARATOR"}],"summary":"The present study, phase III, randomized, controlled, observer-blind, multicenter study, will evaluate safety, tolerability and immunogenicity of two doses of an adjuvanted monovalent influenza vaccine compared with an adjuvanted interpandemic trivalent influenza vaccine in a population of healthy adult and elderly subjects.","primaryOutcome":{"measure":"Number of Subjects With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic Influenza Vaccine.","timeFrame":"Up to 6 days after each vaccination.","effectByArm":[{"arm":"TIV + aH5N1 (18-60 Yrs)","deltaMin":1755,"sd":null},{"arm":"PL+ aTIV (18-60 Yrs)","deltaMin":502,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":2,"countries":["Finland","Germany"]},"refs":{"pmids":["22192847"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":2680},"commonTop":["Injection site pain","Myalgia","Injection site erythema","Headache","Fatigue"]}}